DMSO stock is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-07. Numbers and descriptions here follow the published literature rather than marketing material.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Starting in 1947, Spedding and Powell used displacement ion-exchange chromatography for the separation of the rare-earth elements. Additionally, they showed the ion-exchange separation of 14N and 15N isotopes in ammonia. At the start of the 1950s, Kraus and Nelson demonstrated the use of many analytical methods for metal ions dependent on their separation of their chloride, fluoride, nitrate or sulfate complexes by anion chromatography. Automatic in-line detection was progressively introduced from 1960 to 1980 as well as novel chromatographic methods for metal ion separations. A groundbreaking method by Small, Stevens and Bauman at Dow Chemical Co. unfolded the creation of the modern ion chromatography. Anions and cations could now be separated efficiently by a system of suppressed conductivity detection. In 1979, a method for anion chromatography with non-suppressed conductivity detection was introduced by Gjerde et al. Following it in 1980, was a similar method for cation chromatography. As a result, a period of extreme competition began within the IC market, with supporters for both suppressed and non-suppressed conductivity detection. This competition led to fast growth of new forms and the fast evolution of IC. A challenge that needs to be overcome in the future development of IC is the preparation of highly efficient monolithic ion-exchange columns and overcoming this challenge would be of great importance to the development of IC.
== Products and Services == The company's first product was a dry, synthetic polymer, "DNAstable" (originally “SampleMatrix”), a chemical formulation that stabilized purified DNA at ambient temperature. The company later released RNAstable and CloneStable, dry chemical reagents optimized for stabilizing purified RNA and bacterial plasmid DNA, respectively. In 2007, the German biotechnology company, Qiagen, licensed DNAstable for sale under the trade name QIAsafe. Biomatrica and Qiagen subsequently co-developed QIAsafe Blood, an ambient temperature stabilization reagent for unpurified DNA in whole blood. Later in 2007, Biomatrica released molecular assay enhancement products, PCRboost and STRboost, for enhancement of PCR performed on degraded and trace DNA samples. Liquid versions of DNAstable and RNAstable were launched as DNAstable LD and RNAstable LD in 2011 and 2012, respectively. These liquid products provide more flexibility for diverse experimental formats, including those utilizing automated instrumentation. Biomatrica began commercialization of preanalytical products in 2009 with the launch of its “gard” product line. These products include RNAgard Blood, DNAgard Blood, and DNAgard Tissue and Cells, products designed to stabilize biological samples from collection to analytical testing. In 2013, the company launched a device, DNAgard Saliva, for the collection of salivary DNA samples to be used in a variety of research studies. In 2015, a completely redesigned and improved version of this device was launched under the name DNAgard Saliva HT.
Official website Eli Lilly and Company on OpenSecrets, a website that tracks and publishes data on campaign finance and lobbying Hand book of pharmacy and therapeutics, Science History Institute, c. 1919 Business data for Eli Lilly and Company:
"Just ahead of our time again!" jests Hoffmann. Despite the more commercially appealing sound of the album, it fell short of the sales figures of its predecessor Balls to the Wall in America. Udo remembers the Breaker through Metal Heart era as the time when the band got along best together. Thus this would turn out to be the last album of Accept's golden era, as cracks were soon to appear in the band's solidarity. The 2002 digitally remastered CD edition includes two live bonus tracks, "Love Child" and "Living for Tonite", both taken from the live EP Kaizoku-Ban. The 2013 release from UK-based record label Hear No Evil Recordings contains the live EP itself.
NRgize Lifestyle Cafe (United States) Planet Smoothie – a chain of smoothie restaurants with stores in Alabama, Arizona, Arkansas, California, Florida, Georgia, Maryland, Massachusetts, Nebraska, New York, North Carolina, Pennsylvania, South Carolina, Texas and Virginia. Pinkberry – a chain of frozen dessert restaurants with locations in Canada, Chile, Egypt, India, Indonesia, Japan, Nigeria, Saudi Arabia, Jordan, Panama, Peru, Oman, Qatar, United Arab Emirates, United States, Philippines and Thailand. Ranch One – a chain of restaurants specializing in grilled chicken breast sandwiches, with locations in Kuwait and the United States. Rollerz (California, D.C., Illinois, Nevada and Texas) Samurai Sam's Teriyaki Grill (Kuwait and United States) Surf City Squeeze – a chain of smoothie restaurants with stores in Canada, Saudi Arabia, Curaçao/Netherlands Antilles and United States. Sweet Frog - a chain of frozen yogurt restaurants with stores in the United States (East Coast, South, Mideast, Midwest, West Coast only) and the Dominican Republic. Taco Time (Canada, Kuwait, Curaçao/Netherlands Antilles; and United States, except locations primarily in western Washington state operated by Taco Time Northwest) Tasti D-Lite – a New York-based fast food company which mainly sells frozen dessert products, it has locations in Florida, Maryland, Nevada, New Jersey, New York and Texas.
Sources: en.wikipedia.org
== Therapeutic uses of neohormones == Relaxin has been shown to repair and reverse the symptoms associated with scleroderma (an autoimmune condition affecting connective tissues, blood vessels and internal organs) and fibrosis (thickening, hardening or build up of scar tissue). It also aids in the formation of new blood vessels (angiogenesis). This is also beneficial in wound management and healing. Other potential targets include the use of relaxin within human reproduction, such as in the preparation of the cervix for labour and birth and also as a drug target for breast cancer treatment although much more research is required in this area. Oxytocin is important for many different biological processes including social, maternal and sexual behaviours, pregnancy, milk production, and ejaculation. Agonists and antagonists of oxytocin – development of drugs that can utilise the receptor binding activity of oxytocin is an important therapeutic target as this could be applied to a range of conditions. Oxytocin plays a role in cell proliferation and differentiation in different ways depending on where it is in the body. Understanding the underlying pathways for different localities could help with development of cancer therapies.
Papaverine (Latin papaver, "poppy") is an opium alkaloid antispasmodic drug, used primarily in the treatment of visceral spasms and vasospasms (especially those involving the intestines, heart, or brain), occasionally in the treatment of erectile dysfunction and acute mesenteric ischemia. While it is found in the opium poppy, papaverine differs in both structure and pharmacological action from the analgesic morphine and its derivatives (such as codeine). One study has suggested that excessive consumption of uncooked katuk leaves can cause lung damage due to the high concentrations of papaverine present.
September 21: Malta becomes independent from the UK. September 24: The Mozambican War of Independence begins in Portuguese Mozambique. October 12: The first spaceflight to carry multiple crewman into orbit was conducted by Voskhod 1. October 14: Leonid Brezhnev succeeds Khrushchev to become General Secretary of the Communist Party of the Soviet Union, with Alexei Kosygin as his Premier. October 16: China tests its first atomic bomb. The test makes China the world's fifth nuclear power. October 24: Northern Rhodesia renamed Zambia becomes independent from the UK. November 28: Mariner 4 was launched.
The Detroit Riverfront, for instance, is maintained and developed almost exclusively through nonprofit funding in partnership with public and private enterprises. This model for economic development and revitalization has seen enormous success in Detroit, with the Detroit Riverfront Conservancy raising in excess of $23 million to revitalize and maintain riverfront assets. This model for economic development is so promising that the city has turned to similar partnership strategies to manage, maintain, and revitalize several other city assets. Over the past seventy years, the city of Detroit has experienced a dramatic reduction in its population and economic well-being. This decline has left countless community members in economic turmoil, driving many residents to fall behind on taxes and subject their homes to tax foreclosure. Due to the overassessment of property values based on outdated appraisals, the property taxes on these homes are massively inflated, perpetuating further property foreclosure and community displacement. These foreclosed properties are often turned over to a public auction, where many of them are purchased by wealthy investors looking to take advantage of Detroit's housing market. Proponents of such investment argue that wealthy investors have minimized displacement by redeveloping vacant areas where people did not reside; however, this kind of investment can have additional repercussions beyond residents' physical and economic displacement.
== Legal and regulatory status == European Union: In the EU, Good Clinical Practice is backed and regulated by formal legislation contained in the Clinical Trial Regulation (Officially Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC). A similar guideline for clinical trials of medical devices is the international standard ISO 14155, which is valid in the European Union as a harmonized standard. These standards for clinical trials are sometimes referred to as ICH-GCP or ISO-GCP to differentiate between the two and the lowest grade of recommendation in clinical guidelines. United States: Although ICH GCP guidelines are recommended by the Food and Drug Administration (FDA), they are not statutory in the United States. The National Institutes of Health requires NIH-funded clinical investigators and clinical trial staff who are involved in the design, conduct, oversight, or management of clinical trials to be trained in Good Clinical Practice.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.